-
Posted by
Two Blokes Jul 24 -
Filed in
Stock
-
5 views
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has reported progress across its two main research programmes, as the company moves closer to starting human trials for its gene therapies aimed at tackling age-related conditions. The London-listed group said it is continuing to prepare GF-1002, its lead candidate, for clinical trial authorisation in Europe.
